Thrombolytic Therapy Mechanisms and Applications

Thrombolytic therapy employs pharmacological agents to dissolve pathological thrombi by promoting fibrinolysis. Central to this approach is the conversion of the zymogen plasminogen into the active serine protease plasmin, which degrades fibrin networks within clots. Therapy mechanisms include direct administration of tissue-type plasminogen activator (tPA) or urokinase, which catalyse plasminogen activation, as well as bacterial-derived proteins such as streptokinase and staphylokinase that form complexes to expose plasminogen’s active centre. Advances in molecular engineering have yielded fibrin-targeted variants and multifunctional fusion proteins designed to enhance clot specificity, reduce systemic proteolysis and minimise reperfusion injury. Clinical applications span acute management of myocardial infarction, ischaemic stroke and pulmonary embolism, with catheter-directed approaches extending indications to peripheral arterial occlusion. Contemporary research focuses on refining pharmacokinetics, optimising dosing regimens and mitigating bleeding risk or reocclusion. Emerging strategies include nanoparticle carriers, bispecific constructs and tailored delivery systems to sharpen the therapeutic index and enable personalised fibrinolytic intervention.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Thrombolytic Therapy Mechanisms and Applications publication trend

The graph below shows the total number of articles in thrombolytic therapy mechanisms and applications across all publications each year (not limited to Nature Index journals).

Technical terms

Fibrin: Insoluble protein polymer that forms the structural framework of a blood clot.

Plasminogen: Inactive precursor (zymogen) of plasmin, circulating in plasma.

Plasmin: Serine protease responsible for degrading fibrin and mediating clot dissolution.

Plasminogen activator: Enzyme that converts plasminogen to plasmin (for example, tissue-type plasminogen activator or urokinase).

Staphylokinase: Bacterial protein that binds plasminogen to reveal its active site and generate plasmin.

Alpha2-antiplasmin: Principal plasma inhibitor of plasmin, regulating fibrinolytic activity by neutralising free plasmin.

References

1. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. Journal of Biological Chemistry (1991).
2. Mechanism of Activation of Human Plasminogen by Streptokinase PRESENCE OF ACTIVE CENTER IN STREPTOKINASE-PLASMINOGEN COMPLEX. Journal of Biological Chemistry (1972).
3. In Vitro Characterization of a Multifunctional Staphylokinase Variant with Reduced Reocclusion, Produced from Salt Inducible E. coli GJ1158. BioMed Research International (2013).
4. Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. Journal of Biological Chemistry (1993).